Anthera Pharmaceuticals, Inc.

ANTHOTCHealthcare● Active

$0.00

+$0.00(+0.00%)

Market Cap$26179

P/E Ratio—

52W High$0.001

52W Low$0.0001

Avg Volume2K

Open$0.00

Beta-123.12

Free Cash Flow Financials Revenue

Anthera Pharmaceuticals, Inc. (ANTH) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ANTH · free cash flow · updated Jun 9, 2026

Core FCF metrics

ANTH · FCF · TTM · margin & CAGR

Free cash flow was −$36.9M for FY2017 (fiscal year ending 2017-12-31), up 25.7% year-over-year

FY2017 Free Cash Flow−$36.9M▲ +25.7% YoY

Trailing 12M (TTM)−$32.0Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ANTH · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2017Latest−$36.9M(0M)−$36.9M▲ +25.7%—

FY2016−$48.9M(1M)−$49.7M▼ 60.3%—

FY2015−$30.9M(0M)−$31.0M▼ 21.0%-972.9%

FY2014−$25.6M(0M)−$25.6M▲ +19.8%—

FY2013−$31.9M(0M)−$31.9M▲ +56.8%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ANTH · P/FCF · FCF yield · FCF per share

Anthera Pharmaceuticals, Inc. (ANTH) reported negative free cash flow of −$0.04B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2017 · 2017-12-31

Cash flow statement summary

ANTH · cash flow statement · operating / investing / financing

For FY2017, Anthera Pharmaceuticals, Inc. generated −$36.9M in operating cash flow and spent 0M in capital expenditures, yielding −$36.9M in free cash flow.

Operating Activities

−$36.9M

Cash from core business operations

2017-12-31

Investing Activities

+$0.0M

CapEx, acquisitions & investments

2017-12-31

Financing Activities

+$18.3M

Buybacks, dividends & debt

2017-12-31

FCF FormulaOperating CF (−$36.9M) − |CapEx| (0M) = FCF (−$36.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ANTH vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Anthera Pharmaceuticals, Inc.YOU

ANTH

−$36.9M+25.7%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Anthera Pharmaceuticals, Inc. (ANTH) reported free cash flow of −$36.9M for FY2017 (fiscal year ending 2017-12-31), up 25.7% year-over-year.

Anthera Pharmaceuticals, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 11 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ANTH free cash flow · 8 questions

Anthera Pharmaceuticals, Inc. free cash flow was −$36.9M for FY2017, up 25.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$32.0M.

ANTH free cash flowANTH FCFANTH FCF 2017ANTH free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Anthera Pharmaceuticals, Inc. · Anthera Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026